Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.33 |
| ▸ | CTRC | Q99895 | 2/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9886463 | 1.00 | ALDH1A1 (0.39) | ALDH1A1PRSS1CTRCF2 | |
| SCHEMBL11957439 | 0.81 | — | — | |
| SCHEMBL4405125 | 0.73 | — | — | |
| SCHEMBL762450 | 0.71 | — | — | |
| SCHEMBL1643317 | 0.71 | — | — | |
| SCHEMBL13498357 | 0.71 | — | — | |
| SCHEMBL9516054 | 0.71 | — | — | |
| SCHEMBL8665253 | 0.71 | — | — | |
| SCHEMBL17224585 | 0.71 | — | — | |
| SCHEMBL11957432 | 0.71 | NPSR1 (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019238090-A1 | STRONG BASE-INITIATED N-CARBOXYANHYDRIDE RAPID RING-OPENING POLYMERISATION METHOD | 华东理工大学 | 2019-12-19 | — | — | WO | disclosed |
| US-20120130020-A1 | Poly(Ester Amide)s and Poly(Ester Ether Amide)s With Pendant Crosslinkable Functional Groups | CORNELL UNIVERSITY (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120130020-A1 | Poly(Ester Amide)s and Poly(Ester Ether Amide)s With Pendant Crosslinkable Functional Groups | CORNELL UNIVERSITY (US) | 2012-05-24 | — | — | US | disclosed |
| EP-1913002-B9 | METHOD OF ACYLATING MAYTANSINOL WITH CHIRAL AMINO ACIDS | MILLENNIUM PHARM INC (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-1913002-B1 | METHOD OF ACYLATING MAYTANSINOL WITH CHIRAL AMINO ACIDS | MILLENNIUM PHARM INC (US) | 2011-11-30 | — | — | EP | disclosed |
| US-7598375-B2 | Method of acylating maytansinol with chiral amino acids | MILLENIUM PHARMACEUTICALS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| EP-1913002-A2 | METHOD OF ACYLATING MAYTANSINOL WITH CHIRAL AMINO ACIDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007021674-A2 | METHOD OF ACYLATING MAYTANSINOL WITH CHIRAL AMINO ACIDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037972-A1 | For making maytansinoids with chiral amino acid side chains; maytansinoids may be conjugated to cell-binding agents such as antibodies and are useful therapeutics, especially for treatment of cancer; high yielding methods that avoid or reduce epimerization in coupling of side chain linker | MILLENNIUM PHARMACEUTICALS, INC. | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037972-A1 | For making maytansinoids with chiral amino acid side chains; maytansinoids may be conjugated to cell-binding agents such as antibodies and are useful therapeutics, especially for treatment of cancer; high yielding methods that avoid or reduce epimerization in coupling of side chain linker | MRTO4, SLC43A1, SLC7A1 | ALDH1A1 2721/4885PRSS1 3742/4885CTRC 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.